Fig. 1 | Scientific Reports

Fig. 1

From: Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Fig. 1

Progression-free and overall survival of patients treated with lenvatinib (LEN) according to GNRI. (a) Median progression-free survival (PFS) for GNRI no-risk was 9.86 months (95% CI 7.82–11.86), for GNRI low-risk was 7.04 months (95% CI 5.04–7.96), and for GNRI moderate-to-major risk was 4.54 months (95% CI 3.56–6.0) (p < 0.001). (b) Median overall survival (mOS) for GNRI no-risk was 28.21 months (95% CI 22.46–35.11), for GNRI low-risk was 16.18 months (95% CI 11.71–20.14), and for GNRI moderate-to-major risk was 8.82 months (95% CI 8.21–11.54) (p < 0.001).

Back to article page